BioBreakthroughs Slice of Healthcare LLC

Join us on the latest episode! Our Guest: Colin Weller, VP & GM of Evidence Platform at Medable.
What you'll get out of this episode:
Introduction of Colin Weller: Vice President and GM of Evidence Platform at Medable, Colin Weller discusses his role in advancing clinical research technology to streamline drug approvals.Challenges in Drug Development: Weller details the stagnant pace of drug development, highlighting the industry's need for innovation to improve efficiency and reduce costs.Medable's Ambitious Goals: Aiming to increase the number of drugs approved annually by tenfold through advanced SAS technology and AI, setting a new industry standard.Innovations in Clinical Trials: Medable has already cut study startup times by 50%, utilizing AI and automation to overhaul traditional processes.Future of Digital Clinical Trials: Weller predicts significant advancements in decentralized and digital trials, enhancing patient accessibility and data quality.
To learn more about our guests and their companies:LinkedIn: https://www.linkedin.com/in/colin-weller-294ab58/Company LinkedIn: https://www.linkedin.com/company/medable-inc-/ Website: https://www.medable.com/Our sponsor for this episode are:Sage Growth Partners https://sage-growth.com/
BioBreakthroughs is part of the Slice of Healthcare podcast network:LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guest: Stella K. Vnook, CEO at Likarda.
What you'll get out of this episode:
Stella Vnook, CEO of Likarda, discusses her transition from a science background to the business side of biotech and her journey to becoming CEO.Likarda specializes in core-shell spherification, creating beads with cells for targeted drug delivery, improving viability and efficacy.The company aims to enhance cell therapies, especially in liver cells and hormone therapy, and simplify cell transport logistics.Likarda's future goals include launching off-the-shelf products for osteoarthritis and advancing partnerships in cell therapy and regenerative medicine.Funding strategies and future plans involve a Series A funding round, non-dilutive funding, and efficient use of resources to scale up and innovate.
To learn more about our guests and their companies:LinkedIn: https://www.linkedin.com/in/vnook/Company LinkedIn: https://www.linkedin.com/company/likarda-llc/Website: https://likarda.com/Our sponsor for this episode are:Sage Growth Partners https://sage-growth.com/
BioBreakthroughs is part of the Slice of Healthcare podcast network:LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guest: Samantha Dale Strasser, CEO & Co-Founder at Pepper Bio.
What you'll get out of this episode:
Samantha Dale Strasser, co-founder and Chief Science Officer of Pepper Bio, shares her transition from academia to entrepreneurship, driven by a personal mission to change healthcare outcomes.Pepper Bio, located in Boston, leverages transomics to integrate multiple data sets for precision medicine, aiming to treat diseases that are currently untreatable.Strasser’s focus is on developing treatments for challenging diseases, with an emphasis on oncology, inflammatory diseases, and neurodegenerative disorders.Pepper Bio’s approach in drug discovery combines its own pipeline development with strategic partnerships, speeding up the process of bringing new treatments to the clinic.The company has made significant strides in identifying novel targets and shelved assets, leading to a high success rate in in vivo model validations.
To learn more about our guests and their companies:LinkedIn: https://www.linkedin.com/in/samantha-dale-strasser/Company LinkedIn: https://www.linkedin.com/company/pepperbio/Website: https://pepper.bio/Our sponsor for this episode are:Sage Growth Partners https://sage-growth.com/
BioBreakthroughs is part of the Slice of Healthcare podcast network:LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guest: Cary Claiborne, CEO of Adial Pharmaceuticals.
What you'll get out of this episode:
Meet Cary Claiborne: Discover the visionary CEO behind Adial Pharmaceuticals.Understanding AD04: Dive into the science of this promising new treatment for alcohol use disorder.The Impact of Alcohol Use Disorder: A closer look at the challenges and the need for better treatments.A Glimpse into the Future: Explore how AD04 could revolutionize addiction treatment beyond alcohol use disorder.Adial's Mission and Vision: Hear directly from Claiborne about the company's path forward and commitment to innovation.
To learn more about our guests and their companies:LinkedIn: https://www.linkedin.com/in/cary-claiborne-sr-84a2217/Company LinkedIn: https://www.linkedin.com/company/adialpharma/Website: https://www.adial.com/Our sponsor for this episode are:Sage Growth Partners https://sage-growth.com/
BioBreakthroughs is part of the Slice of Healthcare podcast network:LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guest: Marcio Souza, CEO of Praxis Precision Medicines.
What you'll get out of this episode:
Discussion on innovative CNS drug development on BioBreakthroughs podcast.Learn about Praxis' genetics-inspired approach to tackling complex brain diseases.Souza highlights the challenges and opportunities in CNS treatment, including the impactful EMBOLD and EMBRAVE studies.Discover Praxis Precision Medicines' future prospects and their commitment to revolutionizing patient care in the CNS field.
To learn more about our guests and their companies:LinkedIn: https://www.linkedin.com/in/marcio-souza-2b02837/Company LinkedIn: https://www.linkedin.com/company/praxis-precision-medicines-inc/Website: https://praxismedicines.com/Our sponsor for this episode are:Sage Growth Partners https://sage-growth.com/
BioBreakthroughs is part of the Slice of Healthcare podcast network:LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guest: Steve Reed, Co-Founder & Chief Executive Officer Of HDT Bio
What you'll get out of this episode:
Reed shares his 40-year journey in microbiology and immunology.Discussion on HDT Bio's approach to vaccine development for infectious diseases and cancer.Insight into the Amplify vaccine platform and its impact on global health.Reed's perspective on vaccine accessibility and affordability.Preview of HDT Bio's upcoming projects in oncology.
To learn more about our guests and their companies:LinkedIn: https://www.linkedin.com/in/steven-reed-b23b159b/Company LinkedIn: https://www.linkedin.com/company/hdt-bio/Website: https://www.hdt.bio/Our sponsor for this episode are:Sage Growth Partners https://sage-growth.com/
BioBreakthroughs is part of the Slice of Healthcare podcast network:LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/